Investigational drug · Phase 2
REGN5678
Also called: Nezastomig
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "REGN5678"
First trial start
2019
Aug 12, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN5678", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Metastatic Castration-Resistant Prostate Cancer
- mCRPC
Approved drugs for the same conditions: Prostate cancer · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN5678" as an intervention, largest first.
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03972657 · 345 participants (planned) · Start Aug 12, 2019 · Primary completion Nov 15, 2027
Drug: REGN5678; Cemiplimab · For: Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC)
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 27 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05125016 · 228 participants (planned) · Start Nov 30, 2021 · Primary completion Mar 28, 2030
Drug: REGN4336; REGN5678 · For: Metastatic Castration-resistant Prostate Cancer
Sites: Palo Alto, California; New Haven, Connecticut; Louisville, Kentucky · 14 sites in all
- REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07850921 · 192 participants (planned) · Start Jun 28, 2027 · Primary completion Jul 28, 2031
Drug: REGN21353; Nezastomig and 1 more · For: Metastatic Castration-Resistant Prostate Cancer; mCRPC
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06826768 · 60 participants (planned) · Start Jul 9, 2025 · Primary completion May 1, 2027
Drug: REGN5678; Cemiplimab · For: Prostate Cancer
Sites: Houston, Texas
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06085664 · 42 participants (planned) · Start Dec 4, 2023 · Primary completion Jun 30, 2028
Drug: REGN5678; Piflufolastat F18 · For: Prostate Cancer; Radical Prostatectomy
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.